Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 3/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13201009 | 0.88 | DPP4 (0.54) | HTR2CDPP4 | |
| SCHEMBL13217754 | 0.85 | HTR3A (0.57) | HTR2CTP53ALDH1A1MAPK1DPP4 | |
| SCHEMBL13217574 | 0.83 | HTR2C (0.53) | HTR2CTP53ALDH1A1TSHRMAPK1 | |
| Trifluoroacetic Acid SCHEMBL2958830 | 0.82 | DPP4 (0.49) | HTR2CDPP4 | |
| SCHEMBL13217750 | 0.79 | SMN1; SMN2 (0.45) | ALDH1A1TSHRDPP4HTR3A | |
| SCHEMBL13217743 | 0.79 | PIM1 (0.49) | ALDH1A1DPP4HTR3A | |
| SCHEMBL4068476 | 0.76 | HTR3A (0.62) | ALDH1A1TSHRDPP4HTR3ASOS1 | |
| SCHEMBL13200868 | 0.74 | HTR3A (0.54) | HTR2CDPP4HTR3ASOS1 | |
| SCHEMBL2641132 | 0.73 | HTR2C (0.47) | HTR2CALDH1A1 | |
| SCHEMBL6380045 | 0.73 | DPP4 (0.61) | DPP4HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | DPP4, HDAC1, DPP7 | HTR2C 1288/4885TP53 2431/4885ALDH1A1 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.